1
|
Wu B, Mao ZJ, Wang Z, Wu P, Huang H, Zhao W, Zhang L, Zhang Z, Yin H, Gale RP, Yin B. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine. Acta Haematol 2021; 144:534-541. [PMID: 33626530 DOI: 10.1159/000513696] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 12/03/2020] [Indexed: 11/19/2022]
Abstract
Resistance to cytarabine is an important cause of therapy failure in persons with acute myeloid leukemia (AML). Deoxycytidine kinase, encoded by DCK, catalyzes phosphorylation of cytarabine to cytarabine monophosphate, a necessary step for eventual incorporation of cytarabine triphosphate into DNA and for clinical efficacy. Whether DCK mutations make AML cells resistant to cytarabine is controversial. We studied DCK mutations and messenger RNA (mRNA) concentrations in leukemia cells from 10 subjects with AML who received cytarabine-based therapy and relapsed and in 2 artificially induced cytarabine-resistant AML cell lines. DCK mutations were detected in 4 subjects with AML relapsing after achieving a complete remission and receiving high-dose cytarabine postremission therapy. Most mutations were in exons 4-6 and were not present before therapy. DCK was also mutated in cytarabine-resistant but not parental AML cell lines. DCK mRNA concentrations were significantly decreased in cytarabine-resistant K562 and SHI-1 cells compared with cytarabine-sensitive parental cells. Mutation frequency of DCK and mRNA concentration did not correlate with the extent of cytarabine resistance indicating other factors operate. Overexpression of wild-type DCK restored cytarabine sensitivity to previously resistant leukemia cell lines. Our data contribute to the understanding of cytarabine resistance in persons with AML.
Collapse
MESH Headings
- Cytarabine/pharmacology
- Deoxycytidine Kinase/genetics
- Deoxycytidine Kinase/metabolism
- Drug Resistance, Neoplasm/drug effects
- Drug Resistance, Neoplasm/genetics
- Humans
- K562 Cells
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/enzymology
- Leukemia, Myeloid, Acute/genetics
- Mutation
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
Collapse
Affiliation(s)
- Biao Wu
- Translational Medical Research Center, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
- Department of Laboratory Medicine, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Zhengwei Jenny Mao
- Seattle Cancer Center Alliance, University of Washington Medical Center, Seattle, Washington, USA
| | - Zhi Wang
- Department of Hematology, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Pin Wu
- Department of Hematology, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Hongyu Huang
- Department of Laboratory Medicine, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Wenjun Zhao
- Cyrus Tang Hematology Center, Soochow University, Suzhou, China
| | - Lei Zhang
- Translational Medical Research Center, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Zhou Zhang
- Translational Medical Research Center, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China
| | - Hongchao Yin
- Department of Pathology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Robert Peter Gale
- Department of Immunology and Inflammation, Haematology Research Centre, Imperial College London, London, United Kingdom
| | - Bin Yin
- Translational Medical Research Center, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China,
- Department of Laboratory Medicine, The Affiliated Wuxi No. 2 Peoples Hospital of Nanjing Medical University, Wuxi, China,
- Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, China,
| |
Collapse
|
2
|
Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P. Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells. Cancer Res 2008; 68:2349-57. [DOI: 10.1158/0008-5472.can-07-5528] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Wagner K, Kafert-Kasting S, Heil G, Ganser A, Eder M. Inhibition of granulocyte-macrophage colony-stimulating factor receptor function by a splice variant of the common beta-receptor subunit. Blood 2001; 98:2689-96. [PMID: 11675339 DOI: 10.1182/blood.v98.9.2689] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The receptors for human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 are composed of a ligand-specific alpha-chain (eg, alpha-GM-CSF receptor [alpha-GMR]) and a common beta-subunit (beta-GMR). Ligand binding is believed to induce assembly or conformational changes in preformed complexes containing more than one alpha- and beta-subunit in the activated receptor complex. To analyze the function of a splice variant of beta-GMR with a truncation in the intracellular domain (beta-GMR(IT)), BaF-3 cells expressing human alpha-GMR plus beta-GMR were transfected with beta-GMR(IT). In these cells, coexpression of beta-GMR(IT) inhibits GM-CSF-mediated survival and proliferation in a GM-CSF concentration-dependent manner. To analyze the effect of cytoplasmic assembly of truncated and full-length intracellular beta-GMR sequences, beta-GMR and beta-GMR(IT) were coexpressed with different chimeric alpha/beta-GMR constructs. Whereas both beta-GMR and beta-GMR(IT) generate high-affinity GMR complexes in the presence of alpha/beta-GMR, beta-GMR(IT) inhibits while beta-GMR supports proliferation and cell survival mediated by alpha/beta-GMR. Correspondingly, beta-GMR, but not beta-GMR(IT), generates functional GMR complexes when coexpressed with a defective alpha/beta-GMR construct. These data indicate that beta-GMR(IT) can inhibit survival and mitogenic signaling of the wild-type GMR and demonstrate that recruitment of alternatively spliced receptor subunits may regulate the function of heteromeric cytokine receptors.
Collapse
Affiliation(s)
- K Wagner
- Department of Hematology and Oncology, Hannover Medical School, and the Center for Cell Therapy/Cytonet, Hannover, Germany
| | | | | | | | | |
Collapse
|